PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00226005|
Recruitment Status : Completed
First Posted : September 26, 2005
Last Update Posted : May 9, 2012
The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer.
In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. In adults, blood vessel cells normally divide very rapidly. It is thought that PTK787/ZK222584 may interfere with the growth of new blood vessels. A drug that interferes with the growth of new blood vessels might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Since normal blood vessel cells divide very rarely, it might be possible to stop tumor growth without harming normal tissues.
|Condition or disease||Intervention/treatment||Phase|
|Neoplasm||Drug: PTK787/ZK222584||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||67 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of PTK787/ZK222584 in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Who Failed First-Line Gemcitabine Therapy.|
|Study Start Date :||December 2005|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||February 2010|
Active Comparator: Vatalanib
Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
Other Name: bevacizumab
- To evaluate the 6-month survival rate and time to progression in pancreatic cancer patients treated with PTK787/ZK222584. [ Time Frame: DSMC Schedule ]
The Data Safety Monitoring Board met twice yearly while the study was active (2006-2008) to review data and each of the primary and secondary objectives.
Safety Issue: the only endpoint/outcome measure that was a safety issue was the second one (safety and tolerability of PTK)
- To assess the response rates of patients treated with PTK787/ZK222584. [ Time Frame: DSMC Schedule ]The Data Safety Monitoring Board met twice yearly while the study was active (2006-2008) to review data and each of the primary and secondary objectives.
- To evaluate DCE-MRI as a surrogate of response to PTK787/ZK222584 therapy in pancreatic cancer patients. [ Time Frame: DSMC Schedule ]The Data Safety Monitoring Board met twice yearly while the study was active (2006-2008) to review data and each of the primary and secondary objectives.
- To perform analysis of tissue, blood and plasma markers that may be helpful in assessing the likelihood of benefit from PTK787/ZK222584 therapy. [ Time Frame: DSMC Schedule ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00226005
|United States, Arizona|
|Scottsdale, Arizona, United States, 85259|
|University of Arizona/Arizona Cancer Center|
|Tucson, Arizona, United States, 85724|
|United States, California|
|Tower Hematology Oncology Medical Group|
|Beverly Hills, California, United States, 90211-18500|
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins|
|Baltimore, Maryland, United States, 21231|
|United States, Minnesota|
|Virginia Piper Cancer Institute/Abbott Northwestern Hospital|
|Minneapolis, Minnesota, United States, 55407|
|United States, Tennessee|
|Sarah Cannon Research Institute|
|Nashville, Tennessee, United States, 37203|
|United States, Texas|
|South Texas Oncology and Hematology|
|San Antonio, Texas, United States, 78229|
|Principal Investigator:||Tomislav Dragovich, MD, PhD||University of Arizona/Arizona Cancer Center|